Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
Mayo Clinic
Jonsson Comprehensive Cancer Center
NRG Oncology
NRG Oncology
National Cancer Institute (NCI)
Mayo Clinic
Mayo Clinic
Mayo Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
Children's Oncology Group
National Cancer Institute (NCI)
Stanford University
Children's Oncology Group
University of Michigan Rogel Cancer Center
Jonsson Comprehensive Cancer Center
NRG Oncology
Thomas Jefferson University
Mayo Clinic
University of Iowa
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Mayo Clinic
National Cancer Institute (NCI)
Emory University
Baptist Health South Florida
Mayo Clinic
Mayo Clinic
National Cancer Institute (NCI)
Jonsson Comprehensive Cancer Center
NRG Oncology